Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Pelacarsen (AKCEA-APO(a)-LRx) is a hepatotropic antisense oligonucleotide targeting apolipoprotein(a) that effectively attenuates lipoprotein(a) levels by up to 80% and exhibits favorable tolerability [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry | |
50 mg | Inquiry | Inquiry |
Description | Pelacarsen (AKCEA-APO(a)-LRx) is a hepatotropic antisense oligonucleotide targeting apolipoprotein(a) that effectively attenuates lipoprotein(a) levels by up to 80% and exhibits favorable tolerability [1]. |
In vivo | Mice treated weekly for six weeks with Pelacarsen at doses of 0.3, 1, 3, and 10 mg/kg exhibited dose-dependent decreases in target mRNA expression. The model-predicted ED50 (the dose for 50% of the maximal inhibitory effect) of Pelacarsen on liver apo(a) mRNA and plasma apo(a) protein levels were estimated to be 0.32 mg/kg/week and 0.54 mg/kg/week, respectively. |
Synonyms | TQJ230, AKCEA-APO(a)-LRx, ISIS 681257 |
Molecular Weight | N/A |
CAS No. | 1637637-70-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Pelacarsen 1637637-70-7 TQJ-230 ISIS681257 ISIS-681257 TQJ230 AKCEA-APO(a)-LRx ISIS 681257 TQJ 230 inhibitor inhibit